SYNGENE INTERNATIONAL LIMITED |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 708.6 INR | -0.31% |
|
-3.19% | +1.03% |
| Sales 2024 * | 35.96B 431M | Sales 2025 * | 41.11B 492M | Capitalization | 281B 3.37B |
|---|---|---|---|---|---|
| Net income 2024 * | 4.79B 57.32M | Net income 2025 * | 5.96B 71.35M | EV / Sales 2024 * | 7.6 x |
| Net cash position 2024 * | 8.29B 99.29M | Net cash position 2025 * | 9.1B 109M | EV / Sales 2025 * | 6.62 x |
| P/E ratio 2024 * |
60.3
x | P/E ratio 2025 * |
48.6
x | Employees | 6,847 |
| Yield 2024 * |
0.19% | Yield 2025 * |
0.18% | Free-Float | 44.5% |
More Fundamentals
* Assessed data
More news
Latest transcript on Syngene International Limited
More press releases
| 1 day | -0.31% | ||
| 1 week | -3.19% | ||
| Current month | +0.87% | ||
| 1 month | +5.19% | ||
| 3 months | +0.86% | ||
| 6 months | -9.08% | ||
| Current year | +1.03% |
1 week
703.55
767.00
1 month
662.05767.00
Current year
660.35774.00
1 year
610.10860.25
3 years
510.05860.25
5 years
212.55860.25
10 years
147.50860.25
| Managers | Title | Age | Since |
|---|---|---|---|
Jonathan Hunt
CEO | Chief Executive Officer | 55 | 15-02-28 |
Sibaji Biswas
DFI | Director of Finance/CFO | - | 19-12-17 |
| Chairman | 71 | 94-11-17 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Chairman | 71 | 94-11-17 | |
| Director/Board Member | 67 | 17-07-30 | |
Jonathan Hunt
CEO | Chief Executive Officer | 55 | 15-02-28 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.02% | 4 M€ | -4.41% | - | |
| 0.00% | 117 M€ | -1.38% | - | |
| 0.00% | 34 M€ | +1.04% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-18 | 708.6 | -0.31% | 773,632 |
| 24-04-16 | 710.8 | -1.83% | 733,967 |
| 24-04-15 | 724.1 | -3.33% | 586,867 |
| 24-04-12 | 749 | +2.33% | 2,552,963 |
| 24-04-10 | 732 | +0.18% | 891,266 |
Delayed Quote NSE India S.E., April 18, 2024 at 07:43 am EDT
More quotes
Syngene International Limited is an integrated research, development, and manufacturing services company. The Company is engaged in providing contract research and manufacturing services from lead generation to clinical supplies to pharmaceutical and biotechnology companies worldwide. Its services include drug discovery and development capabilities in medicinal chemistry, biology, in vivo pharmacology, toxicology, custom synthesis, process research and development, current good manufacturing practice (cGMP) manufacturing, formulation, and analytical development, along with clinical development services. It offers SynVent, a therapeutic discovery and development platform for executing drug discovery projects. SynVent's portfolio covers modalities and therapeutic areas ranging from small molecule inhibitors to targeted protein stabilization. It serves the pharmaceutical, biotechnology, and specialty chemical sectors, among others. It operates multi-modal biologics manufacturing facility.
Calendar
2024-04-24
- Q4 2024 Earnings Release
Trading Rating
Investor Rating
ESG Refinitiv
C+
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
8
Last Close Price
708.6
INR
Average target price
761.4
INR
Spread / Average Target
+7.44%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +1.03% | 3.37B | |
| -1.82% | 41.36B | |
| +44.25% | 41.3B | |
| +2.56% | 39.61B | |
| -12.11% | 25.62B | |
| +3.09% | 24.09B | |
| -24.16% | 18.38B | |
| +22.12% | 11.85B | |
| -3.74% | 11.82B | |
| +7.75% | 11.07B |
- Stock Market
- Equities
- SYNGENE Stock
